8:50 am Chair’s Opening Remarks

  • Thomas Tedder Alter E. Geller Professor for Research in Immunology Departments of Immunology & Pediatrics, Duke University Medical Centre
  • Aaron Winkler Immune Tolerance Lead, Inflammation & Immunology, Pfizer

Investigating the Opportunities & Challenges of Autoimmune Disease Models

9:00 am Analysis of Autoreactive B Cell Clones in Patient Tissues Yields Insights in Mechanism of Cell Depletive Treatment


  • Deciphering the effect of B-cell depletion and reduction and its effect on tissues
  • Tracking the detection of multiple auto-reactive B-cells types in patient tissue

9:30 am A Therapeutic Strategy to Target All Sources of IgE & Eliminate the Allergic Immune Response


  • Exploring the heterogeneity between autoimmune diseases and within one disease
  • Discussing the issues with autoimmune disease models, the inability to use genetically uniform mice, and the impact on the translational value
  • Reviewing the lack of a consistent classification of human B cells and the imprecision on the adjudication of different phenotypes to a well-defined population

10:00 am Panel Discussion:Understanding the Regulatory & Commercial Landscape for Autoimmune Diseases


  • Analyzing the cell therapy landscape
  • Assessing the logistics of scaling up new treatments
  • Overview of drug approval and regulation

10:30 am
Morning Break

11:30 am Exploring T Cells: Treg Cell interaction & their Implications in Aiding Therapeutic Strategies

  • Adam Elhofy Chief Medical Officer, COUR Pharmaceuticals


  • Unravelling the Diversity of B&T Cell Directed Drug Modalities
  • Peripheral tolerance, preventing autoimmune diseases and limiting chronic inflammatory diseases
  • Treg instability, plasticity and tissue-specific Treg cells

12:00 pm IMU-935, a potent RORyt inverse agonist, effectively inhibits T helper 17 cells but maintains normal thymocyte development

  • Evelyn Peelen Senior Manager Translational Pharmacology, Immunic Therapeutics


  • Learn how IMU-935 is a potent RORyt inverse agonist
  • Explore how IMU-935 does not induce thymocyte aberrations and thereby allows a normal thymocyte maturation
  • Discuss how IMU-935 is in phase 1 clinical development for psoriasis

12:30 pm Generating EngTregs to Overcome Key Challenges Associated with the Successful Application of Treg Cell Therapeutics


  • Engineering abundant T cell populations with stabilized FOXP3 expression to create a scalable Treg Phenotype
  • Utilizing an inducible chimeric receptor to provide highly specific and tunable IL-2 signaling support
  • Providing tissue specificity and enhanced regulatory functions through antigenspecific CARs or TCRs

1:00 pm
Lunch & Networking

Revolutionizing Emerging Therapeutics & their Autoimmune Disease Applications

2:00 pm Cell Therapy Approaches for the Treatment of Autoimmune Diseases


  • Discovering how cell therapy approaches offer the potential to transform the care of patients with refractory autoimmune diseases
  • Review how cells can be engineered to either delete (e.g. car t approaches) or suppress the autoreactive immune system (e.g. Tregs approaches)
  • Exploring how the background of patients with autoimmune disease differs from oncology patients, and how this influences their approach when being introduced in the clinic

2:30 pm Targeted Biologics That Mobilize a Novel Regulatory cd8 T Cell Network to Reduce the Pathology of Human T Cell Driven Autoimmune Disease


  • Review the modulation of a cytolytic regulatory CD8 T cell population that may prevent autoimmune driven inflammatory cascades
  • Unveil the prevalence of CD8 Treg and their potential dysfunction across a spectrum of autoimmune disorders
  • Discuss the introduction of targeted bispecific molecules that engage regulatory CD8 T cells, causing cytolytic elimination of pathogenic CD4 T cells and reduction of disease severity in aggressive inflammatory models

3:00 pm Exploring VISTA Agonists that Actively Induce T Cell Tolerance

  • Randolf Noelle Professor of Microbiology & Immunology, Dartmouth Medical School


  • Evaluating how the current strategies of T cell tolerance are passive
  • Learn how antibodies to human VISTA actively induce antigen-specific T cell deletion
  • Review studies on deletion of naïve and memory T cells

3:30 pm
Afternoon Break

Incorporating Antigen-Specific & PROTAC/Degrader Approaches to Target Autoimmune Disease

4:00 pm Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases


  • Examine how degraders are heterobifunctional molecules that redirect E3 ligase activity to selectively remove dysregulated proteins of interest via the UPS, that offer an exciting new therapeutic approach for immune targets
  • Unveil how targeting IRAK4 for degradation leads to potent anti-inflammatory responses of TLR activated B cells compared to small-molecule inhibition
  • STAT3 degradation abrogates Th17 development with commensurate T reg increases

4:30 pm Leveraging Combination Therapies and Achieving Functional Tolerance


  • Combination Therapies are often advantageous to patients as AE’s can be reduced
  • Functional tolerance can possibly be optimized by using an induction maintenance concept
  • Side effects from systemic immune suppression are a key roadblock in making immune modulation more widely palatable

5:00 pm Chair’s Closing Remarks and End of Summit

  • Thomas Tedder Alter E. Geller Professor for Research in Immunology Departments of Immunology & Pediatrics, Duke University Medical Centre
  • Aaron Winkler Immune Tolerance Lead, Inflammation & Immunology, Pfizer